Prostatic Neoplasms

• 

  Subject Areas on Research

  • 1,10-Phenanthroline reversibility inhibits proliferation of two human prostate carcinoma cell lines (PC-3 and DU145). 
  • 111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer. 
  • 3-D computer visualization and interactive prostate biopsy simulation leads to an improved systematic technique for the detection of prostate cancer: clinical correlation. 
  • 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. 
  • 6-Methylene progesterone is cytotoxic to human cancer cell lines independent of its 5-alpha-reductase activity. 
  • 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. 
  • A "rolling average" multiple adaptive planning method to compensate for target volume changes in image-guided radiotherapy of prostate cancer. 
  • A 6-Mb high-resolution physical and transcription map encompassing the hereditary prostate cancer 1 (HPC1) region. 
  • A Comparative Effectiveness Trial of Alternate Formats for Presenting Benefits and Harms Information for Low-Value Screening Services: A Randomized Clinical Trial. 
  • A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. 
  • A common variant associated with prostate cancer in European and African populations. 
  • A comparison of conventional 'forward planning' with inverse planning for 3D conformal radiotherapy of the prostate. 
  • A comparison of coplanar four-field techniques for conformal radiotherapy of the prostate. 
  • A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. 
  • A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. 
  • A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. 
  • A decision aid for teaching limitations of prostate cancer screening. 
  • A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. 
  • A dose-volume-based tool for evaluating and ranking IMRT treatment plans. 
  • A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer. 
  • A greedy heuristic using adjoint functions for the optimization of seed and needle configurations in prostate seed implant. 
  • A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. 
  • A human novel gene DERPC on 16q22.1 inhibits prostate tumor cell growth and its expression is decreased in prostate and renal tumors. 
  • A hybrid strategy of offline adaptive planning and online image guidance for prostate cancer radiotherapy. 
  • A knowledge-based approach to improving and homogenizing intensity modulated radiation therapy planning quality among treatment centers: an example application to prostate cancer planning. 
  • A longitudinal assessment of bowel related symptoms and fecal incontinence following radical perineal prostatectomy. 
  • A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. 
  • A metalloporphyrin antioxidant alters cytokine responses after irradiation in a prostate tumor model. 
  • A model for optimizing adenoviral delivery in human cancer gene therapy trials. 
  • A multistate model for the genetic analysis of the ageing process. 
  • A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. 
  • A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. 
  • A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. 
  • A novel human cancer culture model for the study of prostate cancer. 
  • A novel isoform ratio switch of the polypyrimidine tract binding protein. 
  • A novel neoplastic primary tumor-derived human prostate epithelial cell line. 
  • A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models. 
  • A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II. 
  • A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. 
  • A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. 
  • A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. 
  • A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. 
  • A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. 
  • A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. 
  • A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). 
  • A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. 
  • A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. 
  • A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. 
  • A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. 
  • A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. 
  • A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. 
  • A planning quality evaluation tool for prostate adaptive IMRT based on machine learning. 
  • A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate. 
  • A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies. 
  • A prostate screening perspective. 
  • A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. 
  • A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). 
  • A region of interstitial 17q25 allelic loss in ovarian tumors coincides with a defined region of loss in breast tumors. 
  • A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. 
  • A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment. 
  • A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. 
  • A serologic approach to the definition of human prostatic carcinoma antigens. 
  • A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. 
  • A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database. 
  • A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells. 
  • A structural approach to examining prostate cancer risk for rural southern African American men. 
  • A structured literature review to determine the use of the American Society for Therapeutic Radiology and Oncology consensus definition of biochemical failure. 
  • A systematic review of hypofractionation for primary management of prostate cancer. 
  • A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. 
  • A three-dimensional deformable model for segmentation of human prostate from ultrasound images. 
  • A time-dependent statistical model which relates current clinical status to prognosis: application to advanced prostatic cancer. 
  • A transgenic mouse prostate cancer model. 
  • A year of successful cancer vaccines points to a path forward. 
  • ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. 
  • ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. 
  • ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. 
  • ALTERATIONS OF THE P53 GENE ARE ASSOCIATED WITH THE PROGRESSION OF A HUMAN PROSTATE CARCINOMA 
  • APC I1307K and the risk of prostate cancer. 
  • Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. 
  • Abiraterone in metastatic prostate cancer without previous chemotherapy. 
  • Absence of PTEN germ-line mutations in men with a potential inherited predisposition to prostate cancer. 
  • Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. 
  • Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families. 
  • Accessory parotid glands as a site of metastases from outside the head and neck: case report. 
  • Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. 
  • Acoustic radiation force impulse imaging of human prostates ex vivo. 
  • Activated α2-macroglobulin binding to human prostate cancer cells triggers insulin-like responses. 
  • Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. 
  • Activation of Rap1 promotes prostate cancer metastasis. 
  • Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. 
  • Active surveillance for African-American men with prostate cancer: of course! Pro. 
  • Active surveillance for early-stage prostate cancer: review of the current literature. 
  • Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? 
  • Activities and accomplishments of the cancer and leukemia group B genitourinary committee. 
  • Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. 
  • Activity of psoralen-functionalized nanoscintillators against cancer cells upon X-ray excitation. 
  • Acute urinary retention associated with prostatic carcinoma. 
  • Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. 
  • Adaptive prostate IGRT combining online re-optimization and re-positioning: a feasibility study. 
  • Adenocarcinoma of the prostate. I. Tissue sampling considerations. 
  • Adenocarcinoma of the prostate. Part II: Tissue prognosticators. 
  • Adenocarcinoma of the prostate: stage A1. 
  • Adiponectin and prostate cancer mortality: to be or not to be skinny? 
  • Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. 
  • Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. 
  • Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. 
  • Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. 
  • Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. 
  • Adrenocortical hyperplasia occurring with metastatic carcinoma of the prostate: report of a case exhibiting increased urinary aldosterone and glucocorticoid excretion. 
  • Adult Patients' Perspectives on the Benefits and Harms of Overused Screening Tests: a Qualitative Study. 
  • Adult cancer survivors discuss follow-up in primary care: 'not what i want, but maybe what i need'. 
  • Advanced prostate cancer: the future. 
  • Advanced prostatic carcinoma: pulmonary manifestations. 
  • Advanced topics in evidence-based urological oncology: using results of a subgroup analysis. 
  • Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? 
  • African-American heredity prostate cancer study: a model for genetic research. 
  • African-American heredity prostate cancer study: a model for genetic research. 
  • African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center. 
  • After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. 
  • Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. 
  • Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. 
  • Age-specific reference ranges for serum prostate-specific antigen in black men. 
  • Aging and neoplasia. 
  • Agreement between a brief mailed screener and an in-depth telephone survey: observations from the Fresh Start study. 
  • Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial. 
  • Algorithm and performance of a clinical IMRT beam-angle optimization system. 
  • Allelic loss on chromosome 6Q in primary prostate cancer. 
  • Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. 
  • Alterations of the P53 gene are associated with the progression of a human prostate carcinoma. 
  • Altered male physiologic function after surgery for prostate cancer: couple perspective. 
  • Alternative Splicing Provides a Novel Molecular Mechanism for Prostatic Small-cell Neuroendocrine Carcinoma. 
  • Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. 
  • Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. 
  • American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. 
  • American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. 
  • An automatic CT-guided adaptive radiation therapy technique by online modification of multileaf collimator leaf positions for prostate cancer. 
  • An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time. 
  • An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein. 
  • An item response theory-based pain item bank can enhance measurement precision. 
  • Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. 
  • Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. 
  • Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. 
  • Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer. 
  • Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoablation. 
  • Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. 
  • Androgen deprivation therapy for prostate cancer results in significant loss of bone density. 
  • Androgen receptor activation by G(s) signaling in prostate cancer cells. 
  • Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. 
  • Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. 
  • Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. 
  • Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. 
  • Androgen-independent prostate cancer progression in the TRAMP model. 
  • Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. 
  • Androgens promote prostate cancer cell growth through induction of autophagy. 
  • Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer. 
  • Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. 
  • Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. 
  • Angiotropism of human prostate cancer cells: implications for extravascular migratory metastasis. 
  • Anterior rectal wall gastrointestinal stromal tumor presenting clinically as prostatic mass. 
  • Anthropometric risk factors for prostate cancer. 
  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). 
  • Antigenic activity of human urothelial tissue. 
  • Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells. 
  • Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. 
  • Anxiety symptoms prior to a prostate cancer diagnosis: Associations with knowledge and openness to treatment. 
  • Apical soft tissue biopsies predict biochemical failure in radical perineal prostatectomy patients with apical cancer involvement. 
  • Apical surgical margins status in robot-assisted laparoscopic radical prostatectomy does not depend on disease characteristics. 
  • Apparent Diffusion Coefficient Values of the Benign Central Zone of the Prostate: Comparison With Low- and High-Grade Prostate Cancer. 
  • Application of dose compensation in image-guided radiotherapy of prostate cancer. 
  • Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. 
  • Arc-modulated radiation therapy based on linear models. 
  • Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment. 
  • Are we overtreating prostate cancer? 
  • Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. 
  • Assessing adverse events of postprostatectomy radiation therapy for prostate cancer: evaluation of outcomes in the Regione Emilia-Romagna, Italy. 
  • Assessing the Cumulative Contribution of New and Established Common Genetic Risk Factors to Early-Onset Prostate Cancer. 
  • Assessment of anatomic extent and biologic hazard of prostatic adenocarcinoma. 
  • Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors. 
  • Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. 
  • Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. 
  • Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. 
  • Association between Agent Orange and prostate cancer: a pilot case-control study. 
  • Association between exercise and primary incidence of prostate cancer: does race matter? 
  • Association between family history of prostate and breast cancer among African-American men with prostate cancer. 
  • Association between germline variation in the FHIT gene and prostate cancer in Caucasians and African Americans. 
  • Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer. 
  • Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database. 
  • Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. 
  • Association of LEP G2548A and LEPR Q223R polymorphisms with cancer susceptibility: evidence from a meta-analysis. 
  • Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells. 
  • Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy. 
  • Association of uridine diphosphate-glucuronosyltransferase 2B gene variants with serum glucuronide levels and prostate cancer risk. 
  • Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. 
  • Associations between lifestyle factors and quality of life among older long-term breast, prostate, and colorectal cancer survivors. 
  • Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. 
  • Atlas-guided prostate intensity modulated radiation therapy (IMRT) planning. 
  • Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. 
  • Autonomic nerve development contributes to prostate cancer progression. 
  • Awareness, concern, and communication between physicians and patients on bone health in cancer. 
  • B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. 
  • BRCA mutations and risk of prostate cancer in Ashkenazi Jews. 
  • BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. 
  • Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. 
  • Balancing Risks in Prostate-specific Antigen Recurrence: The Fox Versus the Hedgehog. 
  • Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. 
  • Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy. 
  • Baseline prostate-specific antigen testing at a young age. 
  • Bayesian inference for the stereotype regression model: Application to a case-control study of prostate cancer. 
  • Bcl-2 accelerates multistep prostate carcinogenesis in vivo. 
  • Beam orientation selection for intensity-modulated radiation therapy based on target equivalent uniform dose maximization. 
  • Beam-orientation customization using an artificial neural network. 
  • Best screening tests for prostate cancer. 
  • Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). 
  • Bilateral paraneoplastic optic neuropathy and unilateral retinal compromise in association with prostate cancer: a differential diagnostic challenge in a patient with unexplained visual loss. 
  • Binding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores. 
  • Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. 
  • Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. 
  • Biochemical recurrence of prostate cancer. 
  • Biological function and mechanism of miR-33a in prostate cancer survival and metastasis: via downregulating Engrailed-2. 
  • Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer. 
  • Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. 
  • Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. 
  • Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. 
  • Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. 
  • Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. 
  • Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer. 
  • Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study. 
  • Body dimension differences in men with or without prostate cancer. 
  • Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. 
  • Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. 
  • Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates. 
  • Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success. 
  • Brachytherapy using injectable seeds that are self-assembled from genetically encoded polypeptides in situ. 
  • Bradykinin receptor subtype 1 expression and function in prostate cancer. 
  • Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. 
  • CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. 
  • CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. 
  • CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. 
  • CaMKK2: a novel target for shaping the androgen-regulated tumor ecosystem. 
  • Cadmium-induced neoplastic transformation of human prostate epithelial cells. 
  • Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology. 
  • Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer? 
  • Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828. 
  • Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years? 
  • Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? 
  • Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience. 
  • Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. 
  • Cancer survivors' health worries and associations with lifestyle practices. 
  • Cancer-specific concerns and physical activity among recently diagnosed breast and prostate cancer survivors. 
  • Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. 
  • Capromab Pendetide imaging of prostate cancer. 
  • Carbohydrate intake, glycemic index and prostate cancer risk. 
  • Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. 
  • Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. 
  • Carcinoembryonic antigen as an adjunct to determination of clinical stage in prostate cancer. 
  • Carcinogenesis in urogenital sites. 
  • Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. 
  • Carcinoma of the prostate: the therapeutic dilemma. 
  • Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation. 
  • Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. 
  • Cell signaling modifiers in prostate cancer. 
  • Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells. 
  • Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. 
  • Cellular migration and invasion uncoupled: increased migration is not an inexorable consequence of epithelial-to-mesenchymal transition. 
  • Central zone lesions on magnetic resonance imaging: Should we be concerned? 
  • Change in self-efficacy partially mediates the effects of the FRESH START intervention on cancer survivors' dietary outcomes. 
  • Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. 
  • Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer. 
  • Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. 
  • Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. 
  • Chaperones and disease. 
  • Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences. 
  • Characteristics of men reporting for prostate cancer screening. 
  • Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. 
  • Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. 
  • Characterization of a new model of human prostatic cancer: the multicellular tumor spheroid. 
  • Characterization of frequently deleted 6q locus in prostate cancer. 
  • Characterization of prostate-tissue-directed monoclonal antibody, alpha-Pro 13. 
  • Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. 
  • Characterizing stiffness of human prostates using acoustic radiation force. 
  • Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. 
  • Choosing wisely: the American Society for Radiation Oncology's top 5 list. 
  • Chromosome 17q12 variants contribute to risk of early-onset prostate cancer. 
  • Chromosome 8q24 markers: risk of early-onset and familial prostate cancer. 
  • Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. 
  • Chylothorax: a rare complication of metastatic prostatic carcinoma. 
  • Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. 
  • Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer. 
  • Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. 
  • Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. 
  • Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. 
  • Clinical applications of dendritic cell vaccines. 
  • Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study. 
  • Clinical endpoints for drug development in prostate cancer. 
  • Clinical evaluation of positioning verification using digital tomosynthesis and bony anatomy and soft tissues for prostate image-guided radiotherapy. 
  • Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. 
  • Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer. 
  • Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer. 
  • Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. 
  • Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. 
  • Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man. 
  • Clinically localized prostatic carcinoma. 
  • Clinically relevant changes in family history of cancer over time. 
  • Clonality of sarcomatous and carcinomatous elements in sarcomatoid carcinoma of the prostate. 
  • Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. 
  • Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. 
  • Combination hormonal therapy: a reassessment within advanced prostate cancer. 
  • Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. 
  • Combined antegrade and retrograde endoscopic approach for the management of urinary diversion-associated pathology. 
  • Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. 
  • Combined genome-wide scan for prostate cancer susceptibility genes. 
  • Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. 
  • Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. 
  • Common variation in the BRCA1 gene and prostate cancer risk. 
  • Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. 
  • Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. 
  • Comparative morphology of primary and secondary deposits of prostatic adenocarcinoma. 
  • Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. 
  • Comparing radical prostatectomy and brachytherapy for localized prostate cancer. 
  • Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population. 
  • Comparison of Patient Report and Medical Records of Comorbidities: Results From a Population-Based Cohort of Patients With Prostate Cancer. 
  • Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. 
  • Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. 
  • Comparison of online IGRT techniques for prostate IMRT treatment: adaptive vs repositioning correction. 
  • Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. 
  • Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. 
  • Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. 
  • Comparison of similarity measures for rigid-body CT/Dual X-ray image registrations. 
  • Comparison of treatment techniques for conformal radiotherapy of the prostate using dose-volume histograms and normal tissue complication probabilities. 
  • Comparison of ultrasound-guided biopsies and prostatectomy specimens: predictive accuracy of Gleason score and tumor site. 
  • Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. 
  • Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients. 
  • Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry. 
  • Complications and postoperative events after cryosurgery for prostate cancer. 
  • Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. 
  • Computed high b-value diffusion-weighted imaging improves lesion contrast and conspicuity in prostate cancer. 
  • Concordance in the perception of couples recovering from primary surgical treatment of prostate cancer. 
  • Cone-beam-CT guided radiation therapy: A model for on-line application. 
  • Cone-beam-CT guided radiation therapy: technical implementation. 
  • Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. 
  • Contemporary chemotherapeutic approaches for the treatment of hormone-refractory prostate carcinoma. 
  • Contemporary hormonal management of advanced prostate cancer. 
  • Contemporary results of focal therapy for prostate cancer using cryoablation. 
  • Controversies in the treatment of prostate cancer with maximal androgen deprivation. 
  • Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. 
  • Coping with sexual concerns after cancer: the use of flexible coping. 
  • Copper signaling axis as a target for prostate cancer therapeutics. 
  • Correlation of DNA ploidy and histologic diagnosis from prostate core-needle biopsies: is DNA ploidy more sensitive than histology for the diagnosis of carcinoma in small specimens? 
  • Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry. 
  • Correspondence re: E. Hawk, et al., Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the First National Health and Nutrition Examination Survey. Cancer Epidemiol.Biomark. Prev., 9: 523-527, 2000. 
  • Cost comparison of radical retropubic and radical perineal prostatectomy: single institution experience. 
  • Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? 
  • Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. 
  • Counterpoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy. 
  • Creating value in health by understanding and overcoming resistance to de-innovation. 
  • Critical review: is watchful waiting a viable management option for older men with prostate cancer? 
  • Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 
  • Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. 
  • Current health behaviors and readiness to pursue life-style changes among men and women diagnosed with early stage prostate and breast carcinomas. 
  • Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. 
  • Current trends and new frontiers in focal therapy for localized prostate cancer. 
  • Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase. 
  • Cytokine Gene Polymorphisms Associated With Symptom Clusters in Oncology Patients Undergoing Radiation Therapy. 
  • DNA in radical prostatectomy specimens. Prognostic value of tumor ploidy. 
  • Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy. 
  • Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. 
  • Data pooling and analysis to build a preliminary item bank: an example using bowel function in prostate cancer. 
  • Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families. 
  • Defining and treating high-risk prostate cancer: can we do better? 
  • Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. 
  • Defining the Incremental Utility of Prostate Multiparametric Magnetic Resonance Imaging at Standard and Specialized Read in Predicting Extracapsular Extension of Prostate Cancer. 
  • Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? 
  • Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. 
  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. 
  • Design of FRESH START: a randomized trial of exercise and diet among cancer survivors. 
  • Design of the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS). 
  • Detection of human papillomavirus in the prostate by polymerase chain reaction and in situ hybridization. 
  • Detection of metastatic tumors in nude mice: brief communication. 
  • Detection of oncornavirus antigenic activity in human urothelial tissues. 
  • Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. 
  • Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. 
  • Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System. 
  • Development and clinical evaluation of a three-dimensional cone-beam computed tomography estimation method using a deformation field map. 
  • Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. 
  • Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. 
  • Development of a Metastatic Spinal Tumor Frailty Index (MSTFI) Using a Nationwide Database and Its Association with Inpatient Morbidity, Mortality, and Length of Stay After Spine Surgery. 
  • Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. 
  • Development of a method to isolate circulating tumor cells using mesenchymal-based capture. 
  • Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. 
  • Diabetes and prostate cancer risk in the REDUCE trial. 
  • Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. 
  • Diagnostic potential of serum proteomic patterns in prostate cancer. 
  • Diet and exercise intervention adherence and health-related outcomes among older long-term breast, prostate, and colorectal cancer survivors. 
  • Dietary calcium and risk for prostate cancer: a case-control study among US veterans. 
  • Dietary patterns differ between urban and rural older, long-term survivors of breast, prostate, and colorectal cancer and are associated with body mass index. 
  • Differences in baseline characteristics and outcomes at 1- and 2-year follow-up of cancer survivors accrued via self-referral versus cancer registry in the FRESH START Diet and exercise trial. 
  • Differences in self-reported outcomes of open prostatectomy patients and robotic prostatectomy patients in an international web-based survey. 
  • Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. 
  • Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. 
  • Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues. 
  • Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues. 
  • Digital tomosynthesis with an on-board kilovoltage imaging device. 
  • Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor. 
  • Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. 
  • Disparate results between proliferation rates of surgically excised prostate tumors and an in vitro bioassay using sera from a positive randomized controlled trial. 
  • Dissecting the dynamics of serum prostate-specific antigen. 
  • Disseminated intravascular coagulation complicating Ender's nailing of a pathologic fracture in prostatic carcinoma. A case report. 
  • Distinct regions of allelic loss on 13q in prostate cancer. 
  • Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. 
  • Do patients consistently report comorbid conditions over time?: results from the prostate cancer outcomes study. 
  • Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch. 
  • Docetaxel for advanced prostate cancer: how early to start? 
  • Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study. 
  • Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? 
  • Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group. 
  • Does body mass index have an impact on the rate and location of positive surgical margins following robot assisted radical prostatectomy? 
  • Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database. 
  • Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance? 
  • Does preoperative topical antimicrobial scrub reduce positive surgical site culture rates in men undergoing artificial urinary sphincter placement? 
  • Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy? 
  • Does prostate transitional cell carcinoma preclude orthotopic bladder reconstruction after radical cystoprostatectomy for bladder cancer? 
  • Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival? 
  • Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer? 
  • Does transurethral resection of the prostate promote metastatic disease? 
  • Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective? 
  • Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. 
  • Dosimetric and geometric evaluation of a hybrid strategy of offline adaptive planning and online image guidance for prostate cancer radiotherapy. 
  • Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy. 
  • Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy. 
  • Dosimetric effect of intrafraction motion and residual setup error for hypofractionated prostate intensity-modulated radiotherapy with online cone beam computed tomography image guidance. 
  • Dosimetric feasibility of cone-beam CT-based treatment planning compared to CT-based treatment planning. 
  • Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? 
  • Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. 
  • Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. 
  • Drug development in prostate cancer: time to embrace RECIST? 
  • Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo. 
  • Dynamic prediction of metastases after radical prostatectomy for prostate cancer. 
  • ELF3 is a repressor of androgen receptor action in prostate cancer cells. 
  • Early onset baldness and prostate cancer risk. 
  • Early onset prostate cancer has a significant genetic component. 
  • Early onset prostate cancer: predictors of clinical grade. 
  • Early prostate cancer: prevention, treatment modalities, and quality of life issues. 
  • Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. 
  • Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. 
  • Editorial comment. 
  • Editorial comment. 
  • Editorial comment. 
  • Editorial comment. 
  • Editorial comment. 
  • Editorial comment. 
  • Editorial comment. 
  • Editorial comment. Acute lower urinary tract symptoms after prostate brachytherapy with cesium-131. 
  • Editorial comment. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--Implications for a risk-adapted follow-up strategy. 
  • Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation. 
  • Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. 
  • Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. 
  • Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. 
  • Effect of hormones on the growth of virus-transformed hamster prostatic tissue. 
  • Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. 
  • Effect of physician disclosure of specialty bias on patient trust and treatment choice. 
  • Effect of positive end-expiratory pressure on blood loss during retropubic and robot-assisted laparoscopic radical prostatectomy. 
  • Effect of practice integration between urologists and radiation oncologists on prostate cancer treatment patterns. 
  • Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. 
  • Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). 
  • Effect of the first day correction on systematic setup error reduction. 
  • Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. 
  • Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. 
  • Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. 
  • Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer. 
  • Effects of physical and mental health on relationship satisfaction: a dyadic, longitudinal examination of couples facing prostate cancer. 
  • Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. 
  • Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. 
  • Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. 
  • Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. 
  • Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. 
  • Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy. 
  • Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. 
  • Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. 
  • Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. 
  • Elevated risk of prostate cancer among men with Lynch syndrome. 
  • Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. 
  • Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. 
  • Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. 
  • Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. 
  • Emerging treatment options for patients with castration-resistant prostate cancer. 
  • Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. 
  • Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer. 
  • Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. 
  • Enzalutamide in metastatic prostate cancer before chemotherapy. 
  • Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades. 
  • Epidemiology and screening for prostate cancer. 
  • Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. 
  • Epidermal growth factor receptor gene analysis in renal cell carcinoma. 
  • Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6. 
  • Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer. 
  • Erectile function outcome reporting after clinically localized prostate cancer treatment. 
  • Erythropoietin and erythropoietin receptor expression in human prostate cancer. 
  • Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy. 
  • Establishment and characterization of a new human prostatic carcinoma cell line (DuPro-1). 
  • Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. 
  • European Association of Urology Position Statement on the Role of the Urologist in the Management of Male Hypogonadism and Testosterone Therapy. 
  • European Association of Urology position statement on screening for prostate cancer. 
  • Evaluating measurement invariance across assessment modes of phone interview and computer self-administered survey for the PROMIS measures in a population-based cohort of localized prostate cancer survivors. 
  • Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. 
  • Evaluation of a contour-alignment technique for CT-guided prostate radiotherapy: an intra- and interobserver study. 
  • Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. 
  • Evaluation of an artificial intelligence guided inverse planning system: clinical case study. 
  • Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer. 
  • Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. 
  • Evaluation of ligand-dependent changes in AR structure using peptide probes. 
  • Evaluation of multiple image-based modalities for image-guided radiation therapy (IGRT) of prostate carcinoma: a prospective study. 
  • Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. 
  • Evaluation of the paracrine and endocrine effects of genitourinary tumor produced growth factors. 
  • Evaluations of an adaptive planning technique incorporating dose feedback in image-guided radiotherapy of prostate cancer. 
  • Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. 
  • Evidence for a novel hybrid immunotoxin recognizing ricin A-chain by one antigen-combining site and a prostate-restricted antigen by the remaining antigen-combining site: potential for immunotherapy. 
  • Evidence for a pro-proliferative feedback loop in prostate cancer: the role of Epac1 and COX-2-dependent pathways. 
  • Evidence for an alternative glycolytic pathway in rapidly proliferating cells. 
  • Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study. 
  • Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. 
  • Evolution of the concept of focal therapy for prostate cancer. 
  • Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003. 
  • Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. 
  • Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. 
  • Exercise among breast and prostate cancer survivors--what are their barriers? 
  • Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. 
  • Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time? 
  • Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. 
  • Experience with Gleason's histopathologic grading in prostatic cancer. 
  • Exploring cancer support needs for older African-American men with prostate cancer. 
  • Exploring the Margin Recipe for Online Adaptive Radiation Therapy for Intermediate-Risk Prostate Cancer: An Intrafractional Seminal Vesicles Motion Analysis. 
  • Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. 
  • Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients. 
  • Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. 
  • Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. 
  • Extant health behaviors and uptake of standardized vs tailored health messages among cancer survivors enrolled in the FRESH START trial: a comparison of fighting-spirits vs fatalists. 
  • Extended field radiation therapy versus delayed hormonal therapy in node positive prostatic adenocarcinoma. 
  • Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. 
  • External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence. 
  • External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. 
  • External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database. 
  • Extreme hypofractionation for prostate cancer. 
  • FDG PET/CT Imaging of Prostate Carcinosarcoma. 
  • FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. 
  • Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners. A pilot study of telephone-based coping skills training. 
  • Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. 
  • Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. 
  • Factors predicting prostatic biopsy Gleason sum under grading. 
  • Family history of prostate cancer and relapse after definitive external beam radiation therapy. 
  • Feasibility, acceptability and preliminary psychological benefits of mindfulness meditation training in a sample of men diagnosed with prostate cancer on active surveillance: results from a randomized controlled pilot trial. 
  • Features of the metabolic syndrome and prostate cancer in African-American men. 
  • Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. 
  • Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. 
  • Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. 
  • Fine-mapping the putative chromosome 17q21-22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysis. 
  • First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. 
  • First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. 
  • Fish oil slows prostate cancer xenograft growth relative to other dietary fats and is associated with decreased mitochondrial and insulin pathway gene expression. 
  • Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy. 
  • Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen. 
  • Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. 
  • Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. 
  • Flow cytometric analysis of comedocarcinoma of the prostate: an uncommon histopathological variant of prostatic adenocarcinoma. 
  • Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. 
  • Focal Cryotherapy for Localized Prostate Cancer. 
  • Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. 
  • Focal cryotherapy for prostate cancer. 
  • Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. 
  • Focal therapy for prostate cancer. 
  • Focal therapy for prostate cancer: pathologic basis. 
  • Focal therapy for prostate cancer: possibilities and limitations. 
  • Focal therapy in prostate cancer-report from a consensus panel. 
  • Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria. 
  • Focal therapy of prostate cancer: making steady progress toward a first-line image-guided treatment modality. 
  • Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. 
  • Focusing on testosterone. 
  • Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. 
  • Fostering informed decisions: a randomized controlled trial assessing the impact of a decision aid among men registered to undergo mass screening for prostate cancer. 
  • Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. 
  • Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. 
  • From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer. 
  • Functional status declines among cancer survivors: trajectory and contributing factors. 
  • Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. 
  • Gene therapy for prostate cancer. 
  • Gene therapy for prostate cancer. 
  • Gene therapy for prostate cancer: where are we now? 
  • Genetic alterations in prostate adenocarcinoma. 
  • Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. 
  • Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence. 
  • Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. 
  • Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. 
  • Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. 
  • Genome-wide association scan for variants associated with early-onset prostate cancer. 
  • Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. 
  • Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. 
  • Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC). 
  • Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. 
  • Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23. 
  • Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: significant evidence for linkage at chromosome 15q12. 
  • Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. 
  • Geometric and dosimetric evaluations of an online image-guidance strategy for 3D-CRT of prostate cancer. 
  • Germ-line mutations of the macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-American men. 
  • Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. 
  • Germline genetic variants in men with prostate cancer and one or more additional cancers. 
  • Germline mutations in HOXB13 and prostate-cancer risk. 
  • Gleason Grading, Biochemical Failure, and Prostate Cancer-Specific Death. 
  • Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis. 
  • Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. 
  • Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. 
  • Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line. 
  • Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse. 
  • Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites. 
  • Group trajectory analysis helps to identify older cancer survivors who benefit from distance-based lifestyle interventions. 
  • Guideline for the management of clinically localized prostate cancer: 2007 update. 
  • HEPSIN inhibits cell growth/invasion in prostate cancer cells. 
  • HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. 
  • HOXB13 and other high penetrant genes for prostate cancer. 
  • HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). 
  • HOXB13 mutations and prostate cancer risk. 
  • Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. 
  • Heat shock protein 70 (HSP70) does not prevent the inhibition of cell growth in DU-145 cells treated with TGF-beta1. 
  • Helping patients with localized prostate carcinoma manage uncertainty and treatment side effects: nurse-delivered psychoeducational intervention over the telephone. 
  • Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. 
  • Hereditary link: scientists seek clues in genetic risks for prostate cancer. 
  • Hereditary prostate cancer as a feature of Lynch syndrome. 
  • Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci. 
  • Hereditary prostate cancer in African-American families. 
  • Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. 
  • High Dimensional Variable Selection with Error Control. 
  • High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. 
  • High-intensity focused ultrasound for focal therapy: reality or pitfall? 
  • High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. 
  • High-risk prostate cancer and radical prostatectomy in the setting and context of multidisciplinary care. 
  • Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. 
  • Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings. 
  • Highlights in advanced prostate cancer from the 2014 American Society of Clinical Oncology genitourinary cancers symposium: commentary. 
  • Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma. A direct comparison. 
  • Histologic grading as predictor of response to chemotherapy in patients with prostatic adenocarcinoma. 
  • Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. 
  • Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. 
  • Hormone naïve prostate cancer: predicting and maximizing response intervals. 
  • Hot topic of cancer survivorship and the 'seven deadly sins'. 
  • How and why a generation of radiologists must be trained to accurately interpret prostate mpMRI. 
  • How to select the right patients for focal therapy of prostate cancer? 
  • Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. 
  • Human papillomavirus types 16 and 18 are not involved in human prostate carcinogenesis: analysis of archival human prostate cancer specimens by differential polymerase chain reaction. 
  • Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. 
  • Hypercholesterolemia and prostate cancer: a hospital-based case-control study. 
  • Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. 
  • Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer. 
  • Hypofractionation for clinically localized prostate cancer. 
  • Hypofractionation for prostate cancer: a critical review. 
  • Hypofractionation for prostate cancer: tested and proven. 
  • IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. 
  • IFNgamma induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential. 
  • IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men. 
  • INSPstI polymorphism and prostate cancer in African-American men. 
  • Identification and Functional Validation of Reciprocal microRNA-mRNA Pairings in African American Prostate Cancer Disparities. 
  • Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. 
  • Identification and characterization of proximal 6q deletions in prostate cancer. 
  • Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. 
  • Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. 
  • Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer. 
  • Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer. 
  • Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. 
  • Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. 
  • Identifying Clinically Significant Prostate Cancers using 3-D In Vivo Acoustic Radiation Force Impulse Imaging with Whole-Mount Histology Validation. 
  • Identifying appropriate patients for early salvage radiotherapy after prostatectomy. 
  • Identifying susceptibility genes for prostate cancer--a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. 
  • Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. 
  • Imaging alternative splicing in living cells. 
  • Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen. 
  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. 
  • Impact of NADiA ProsVue PSA slope on secondary treatment decisions after radical prostatectomy. 
  • Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. 
  • Impact of comorbidity on health-related quality of life after prostate cancer treatment: combined analysis of two prospective cohort studies. 
  • Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: a population-based study. 
  • Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. 
  • Impact of pelvic lymphadenectomy in patients with prostatic adenocarcinoma. 
  • Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. 
  • Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. 
  • Impact of race on survival in men with metastatic hormone-refractory prostate cancer. 
  • Impact of radical prostatectomy in the management of clinically localized disease. 
  • Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. 
  • Implementation of a web-based prostate cancer decision site. 
  • Importance of serum hemoglobin in hormone refractory prostate cancer. 
  • Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. 
  • Improvement in prostate cancer survival over time: a 20-year analysis: the Will Rogers phenomenon returns. 
  • Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma. 
  • Improvements in prostate radiotherapy from the customization of beam directions. 
  • In Reply to Fiorino and Cozzarini. 
  • In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. 
  • In regard to Brenner et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio) similar to late-responding normal tissue. 
  • In regard to Ghaly et al., IJROBP 2003;55:1288-1293. 
  • In regards to Wallner et al: (125)I versus (103)PD for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial (Int J Radiat Oncol Biol Phys 2003;57:1297-1303). 
  • In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma. 
  • In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. 
  • In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. 
  • In vivo regulation of hTERT expression and telomerase activity by androgen. 
  • Increased optical magnification from 2.5x to 4.3x with technical modification lowers the positive margin rate in open radical retropubic prostatectomy. 
  • Increased resistance of tumor cells to hyperthermia mediated by integrin-linked kinase. 
  • Increased survival with enzalutamide in prostate cancer after chemotherapy. 
  • Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. 
  • Indications and practice with androgen deprivation therapy. 
  • Indium-111 capromab pendetide (ProstaScint) images before and after salvage radiation therapy. 
  • Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. 
  • Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. 
  • Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. 
  • Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. 
  • Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. 
  • Inferences about prostate intrafraction motion from pre- and posttreatment volumetric imaging. 
  • Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. 
  • Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. 
  • Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells. 
  • Influence of tumour size on human prostate tumour metastasis in athymic nude mice. 
  • Informed Decision Making: Assessment of the Quality of Physician Communication about Prostate Cancer Diagnosis and Treatment. 
  • Informed consent. From bodily invasion to the seemingly mundane. 
  • Infrequent RAS oncogene mutations in human prostate cancer. 
  • Inhibition of NF-kappaB1 and NF-kappaB2 activation in prostate cancer cells treated with antibody against the carboxyl terminal domain of GRP78: effect of p53 upregulation. 
  • Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. 
  • Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. 
  • Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. 
  • Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. 
  • Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. 
  • Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. 
  • Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. 
  • Initiation of salvage therapy for prostate cancer. 
  • Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy. 
  • Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. 
  • Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. 
  • Integral dose conservation in radiotherapy. 
  • Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. 
  • Integrative molecular profiling of routine clinical prostate cancer specimens. 
  • Integrin involvement in freeze resistance of androgen-insensitive prostate cancer. 
  • Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. 
  • Intensity-modulated radiotherapy optimization with gEUD-guided dose-volume objectives. 
  • Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. 
  • Interest in genetic prostate cancer susceptibility testing among african American men. 
  • Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. 
  • Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. 
  • Interstitial brachytherapy for prostate cancer--just an expensive variant of 'watchful waiting'? 
  • Intracranial metastatic adenocarcinoma of the prostate presenting as visual disturbance. 
  • Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. 
  • Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. 
  • Intratumoral inflammation is associated with more aggressive prostate cancer. 
  • Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. 
  • Investigating 3D tumor distribution for optimized diagnosis of prostate cancer. 
  • Investigating the distribution of prostate cancer using three-dimensional computer simulation. 
  • Investigation momentum: the relentless pursuit to resolve uncertainty. 
  • Investigation of phosphoprotein signatures of archived prostate cancer tissue specimens via proteomic analysis. 
  • Investigation of the PSF-choice method for reduced lipid contamination in prostate MR spectroscopic imaging. 
  • In vitro and in vivo evaluation of resveratrol and 3,5-dihydroxy-4'-acetoxy-trans-stilbene in the treatment of human prostate carcinoma and melanoma. 
  • Ion therapy of prostate cancer: daily rectal dose reduction by application of spacer gel. 
  • Is NNT AOK? 
  • Is PSA related to serum cholesterol and does the relationship differ between black and white men? 
  • Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer? 
  • Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? 
  • Is grade or stage of primary importance in determining the outcome after radical prostatectomy for disease clinically confined to the prostate? 
  • Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. 
  • Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? No. 
  • Is the PSA test useless? 
  • Is there a role for a low-carbohydrate ketogenic diet in the management of prostate cancer? 
  • Isolation of a human prostate carcinoma cell line (DU 145). 
  • Ivory vertebra on 18F-sodium fluoride scan: an old sign in a new modality. 
  • Keeping an Open Mind About Novel Concepts for Management of Prostate Cancer. 
  • Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. 
  • Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. 
  • Knowledge-based IMRT treatment planning for prostate cancer. 
  • Laparoscopic intestinal stomas. 
  • Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma. 
  • Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. 
  • Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors. 
  • Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD. 
  • Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis. 
  • Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells. 
  • Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen. 
  • Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis. 
  • Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. 
  • Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. 
  • Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. 
  • Liver and prostate adenocarcinoma: an "estrogen-free" environment? 
  • Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. 
  • Long-term dietary outcomes of the FRESH START intervention for breast and prostate cancer survivors. 
  • Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml. 
  • Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. 
  • Long-term outcomes of the FRESH START trial: exploring the role of self-efficacy in cancer survivors' maintenance of dietary practices and physical activity. 
  • Long-term physical activity outcomes of home-based lifestyle interventions among breast and prostate cancer survivors. 
  • Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). 
  • Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. 
  • Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. 
  • Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: the Flint Men's Health Study. 
  • Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. 
  • Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. 
  • Loss of cell surface TFII-I promotes apoptosis in prostate cancer cells stimulated with activated α₂ -macroglobulin. 
  • Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer. 
  • Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer. 
  • Loss of uteroglobin expression in prostate cancer: relationship to advancing grade. 
  • Low-carbohydrate diets and prostate cancer: how low is "low enough"? 
  • Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. 
  • Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other. 
  • Low-risk prostate cancer patient: active treatment. 
  • Lymph node staging in potentially curable prostatic carcinoma. 
  • Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB. 
  • M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer. 
  • MR imaging in adenocarcinoma of the prostate: interobserver variation and efficacy for determining stage C disease. 
  • MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. 
  • Magnetic separation of acoustically focused cancer cells from blood for magnetographic templating and analysis. 
  • Main outcomes of the FRESH START trial: a sequentially tailored, diet and exercise mailed print intervention among breast and prostate cancer survivors. 
  • Male breast cancer during treatment with leuprolide for prostate cancer. 
  • Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey. 
  • Management of Prostate Cancer in the Elderly. 
  • Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. 
  • Management of metastatic prostatic cancer. 
  • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. 
  • Management of patients with concurrent primary tumors of bladder and prostate. 
  • Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. 
  • Management of the patient with a rising PSA alone. 
  • Managing advanced prostate cancer with Viadur (leuprolide acetate implant). 
  • Masculinity beliefs predict psychosocial functioning in African American prostate cancer survivors. 
  • Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. 
  • Maximizing outcomes in genitourinary cancers across the treatment continuum. 
  • Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903. 
  • Measuring illness uncertainty in men undergoing active surveillance for prostate cancer. 
  • Medical malpractice and prostate brachytherapy. 
  • Medical technologies for the diagnosis of prostate cancer. 
  • Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. 
  • Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. 
  • Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. 
  • Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. 
  • Metastatic prostate cancer in a transgenic mouse. 
  • Metastatic rhabdomyosarcoma presenting as intracranial hemorrhage: imaging findings. 
  • Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. 
  • Metformin use and risk of prostate cancer: results from the REDUCE study. 
  • MicroRNA-182 and microRNA-200a control G-protein subunit α-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells. 
  • Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in Men: The Cooper Center Longitudinal Study. 
  • Mn porphyrins as novel molecular magnetic resonance imaging contrast agents. 
  • Mn-porphyrins as novel molecular magnetic resonance imaging contrast agents. 
  • Modeling cancer progression via pathway dependencies. 
  • Moderators of an uncertainty management intervention: for men with localized prostate cancer. 
  • Modulation of the unfolded protein response by GRP78 in prostate cancer. 
  • Modulation of the unfolded protein response in prostate cancer cells by antibody-directed against the carboxyl-terminal domain of GRP78. 
  • Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. 
  • Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk. 
  • Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients. 
  • Molecular implications of the antiandrogen withdrawal syndrome. 
  • Molecular markers in prostate cancer: the role in preoperative staging. 
  • Molecular mechanisms underlying the potentially adverse effects of folate. 
  • Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy. 
  • Monte Carlo calculation of imaging doses from diagnostic multidetector CT and kilovoltage cone-beam CT as part of prostate cancer treatment plans. 
  • Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. 
  • Morphologic and immunologic studies of human prostatic carcinoma. 
  • Morphological and biochemical studies of virus (SV40) transformed prostatic tissue. 
  • Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and, microvessel density. 
  • Most of patients with localized prostate cancer will be treated in the future? | Opinion: No. 
  • Mucinous adenocarcinoma of the prostate. 
  • Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. 
  • Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. 
  • Multimodal therapy of prostatic cancer. 
  • Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. 
  • Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer. 
  • Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report. 
  • Multiple regions within 8q24 independently affect risk for prostate cancer. 
  • Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma. 
  • Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. 
  • Multivariate models as predictors of pathological stage using Gleason score, clinical stage, and serum prostate-specific antigen. 
  • Multivariate statistical analysis for pathologist. Part I, The logistic model. 
  • Mutational landscape of candidate genes in familial prostate cancer. 
  • Mutations of the p16 gene product are rare in prostate cancer. 
  • NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy. 
  • NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy. 
  • NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015. 
  • NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. 
  • National Cancer Institute Prostate Cancer Genetics Workshop. 
  • Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls. 
  • Neoadjuvant androgen-deprivation therapy prior to radical prostatectomy: con. 
  • Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. 
  • Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. 
  • Nerve-sparing focal cryoablation of prostate cancer. 
  • Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. 
  • New advances in focal therapy for early stage prostate cancer. 
  • New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. 
  • New data, new paradigms for treating patients with prostate cancer. Conclusion. 
  • New data, new paradigms for treating patients with prostate cancer: introduction. 
  • New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. 
  • New drug development in metastatic prostate cancer. 
  • New drugs in prostate cancer. 
  • Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study. 
  • Novel chemotherapies in development for management of castration-resistant prostate cancer. 
  • Novel techniques for the treatment of localized prostate cancer: evidence of efficacy? 
  • Novel therapeutic approaches to advanced prostate cancer. 
  • Novel therapies for the treatment of advanced prostate cancer. 
  • Nutrition, dietary interventions and prostate cancer: the latest evidence. 
  • Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. 
  • Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. 
  • Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. 
  • Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. 
  • Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. 
  • Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. 
  • Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. 
  • Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. 
  • On model specification and selection of the Cox proportional hazards model. 
  • On-line re-optimization of prostate IMRT plans for adaptive radiation therapy. 
  • Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer? 
  • Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. 
  • Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. 
  • Optimization of PSA screening policies: a comparison of the patient and societal perspectives. 
  • Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. 
  • Optimized prostate biopsy via a statistical atlas of cancer spatial distribution. 
  • Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. 
  • Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. 
  • Osteopontin has a protective role in prostate tumor development in mice. 
  • Osteosarcoma after radiotherapy for prostate cancer. 
  • Outcome profiles of locoregional disease after radical prostatectomy and radiotherapy. 
  • Outcome research: prostate cancer databases. 
  • Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. 
  • Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. 
  • Overexpression of hMTH in peripheral lymphocytes and risk of prostate cancer: a case-control analysis. 
  • Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. 
  • PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. 
  • PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. 
  • PDEF in prostate cancer. 
  • PFT-alpha inhibits antibody-induced activation of p53 and pro-apoptotic signaling in 1-LN prostate cancer cells. 
  • PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. 
  • PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. 
  • PSA thresholds for prostate cancer detection. 
  • PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. 
  • PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. 
  • PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. 
  • Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. 
  • Palliative radiotherapy for prostate cancer. 
  • Paraneoplastic limbic encephalitis associated with small cell carcinoma of the prostate. 
  • Pathologic basis of focal therapy for early-stage prostate cancer. 
  • Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. 
  • Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. 
  • Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. 
  • Patient and family communication during consultation visits: The effects of a decision aid for treatment decision-making for localized prostate cancer. 
  • Patient preferences for treatments to delay bone metastases. 
  • Patient selection for experimental adjuvant therapy after radical prostatectomy. 
  • Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. 
  • Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. 
  • Pelvic lymphadenectomy is not essential to staging accuracy in all patients with localized prostate cancer. 
  • Penalized likelihood fluence optimization with evolutionary components for intensity modulated radiation therapy treatment planning. 
  • Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover. 
  • Peptidyl membrane-interactive molecules are cytotoxic to prostatic cancer cells in vitro. 
  • Percent tumor involvement and risk of biochemical progression after radical prostatectomy. 
  • Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. 
  • Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. 
  • Percentage of tumor and tumor length in prostate biopsy specimens: a study of American veterans. 
  • Percentage of tumor in prostatectomy specimens: a study of American Veterans. 
  • Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance. 
  • Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method. 
  • Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation. 
  • Periprostatic Fat: A Risk Factor for Prostate Cancer? 
  • Personalized prediction of tumor response and cancer progression on prostate needle biopsy. 
  • Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. 
  • Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. 
  • Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. 
  • Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer. 
  • Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. 
  • Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. 
  • Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. 
  • Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. 
  • Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. 
  • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. 
  • Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. 
  • Phase II study of etoposide for carcinoma of the prostate. 
  • Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. 
  • Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. 
  • Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions. 
  • Physicians' attitudes about shared decision making for prostate cancer screening. 
  • Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. 
  • Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. 
  • Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. 
  • Plasminogen structural domains exhibit different functions when associated with cell surface GRP78 or the voltage-dependent anion channel. 
  • Platelet-derived growth factor receptors: a therapeutic target in solid tumors. 
  • Point/Counterpoint. Online adaptive planning for prostate cancer radiotherapy is necessary and ready now. 
  • Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients. 
  • Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. 
  • Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. 
  • Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population. 
  • Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men. 
  • Population screening for prostate cancer and emerging concepts for young men. 
  • Positive margins: is adjunctive radiation therapy indicated? 
  • Possible mechanism for seeding of tumor during radical prostatectomy. 
  • Post-radical prostatectomy management options for positive surgical margins: argument for observation. 
  • Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. 
  • Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. 
  • Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. 
  • Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. 
  • Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. 
  • Potential selection bias in a community-based study of PSA levels in African-American men. 
  • Potentiation of signal transduction mitogenesis and cellular proliferation upon binding of receptor-recognized forms of alpha2-macroglobulin to 1-LN prostate cancer cells. 
  • Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. 
  • Predicting and monitoring results of therapy. 
  • Predicting biopsy-proven prostate cancer recurrence following cryosurgery. 
  • Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. 
  • Predicting non-organ-confined prostate cancer in men diagnosed after 2000. 
  • Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy. 
  • Predicting prostate biopsy results: The importance of PSA, age, and race. 
  • Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. 
  • Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. 
  • Predicting the pathology results of radical prostatectomy from preoperative information: a validation study. 
  • Predicting tumor failure in prostate carcinoma after definitive radiation therapy: limitations of models based on prostate-specific antigen, clinical stage, and Gleason score. 
  • Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. 
  • Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. 
  • Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. 
  • Predictive probability of serum prostate-specific antigen for prostate cancer: an approach using Bayes rule. 
  • Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. 
  • Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 
  • Predictors of extracapsular extension and positive margins in African American and white men. 
  • Predictors of lymphatic spread in prostatic adenocarcinoma: uro-oncology research group study. 
  • Predictors of prolonged operative time during robot-assisted laparoscopic radical prostatectomy. 
  • Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. 
  • Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. 
  • Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET. 
  • Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance. 
  • Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy. 
  • Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. 
  • Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. 
  • Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy. 
  • Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. 
  • Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. 
  • Prevalence and correlates of vitamin and supplement usage among men with a family history of prostate cancer. 
  • Prevalence of erectile dysfunction in men screened for prostate cancer. 
  • Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. 
  • Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy. 
  • Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial. 
  • Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. 
  • Primary care providers' perspectives on discontinuing prostate cancer screening. 
  • Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer. 
  • Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center. 
  • Production of beta-human chorionic gonadotropin by prostatic adenocarcinoma and transitional cell carcinoma of the upper urinary tract. 
  • Production of monoclonal antibody alpha Pro3 recognizing a human prostatic carcinoma antigen. 
  • Prognosis of patients with stage D1 prostatic adenocarcinoma. 
  • Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. 
  • Prognostic significance of DNA ploidy in carcinoma of prostate. 
  • Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. 
  • Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. 
  • Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. 
  • Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. 
  • Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. 
  • Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. 
  • Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. 
  • Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. 
  • Prohibitin mutations are uncommon in prostate cancer families linked to chromosome 17q. 
  • Proliferative index determination in prostatic carcinoma tissue: is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage? 
  • Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data. 
  • Properties of prostatic cultures transformed by SV40. 
  • Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. 
  • ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. 
  • Prostate Cancer and Prostatic Diseases. Report from Durham. 
  • Prostate Cancer, Version 1.2016. 
  • Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation. 
  • Prostate and transitional cell carcinoma: radioimmunoassay of viral tumor-associated antigens. 
  • Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. 
  • Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. 
  • Prostate biopsy in selecting candidates for hemiablative focal therapy. 
  • Prostate biopsy quantitative histology as a staging and prognostic factor. 
  • Prostate brachytherapy: a descriptive analysis from CaPSURE. 
  • Prostate cancer 1997--practicing what we preach. 
  • Prostate cancer and chip specimens: complete versus partial sampling. 
  • Prostate cancer and the hypofractionation hypothesis. 
  • Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. 
  • Prostate cancer early detection practices among men with a family history of disease. 
  • Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. 
  • Prostate cancer gene therapy. 
  • Prostate cancer in African Americans: relationship of patient and partner self-efficacy to quality of life. 
  • Prostate cancer in North Carolina. 
  • Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. 
  • Prostate cancer in men of African origin. 
  • Prostate cancer in the Baby Boomer generation: results from CaPSURE. 
  • Prostate cancer in the late 1990s: hormone refractory disease options. 
  • Prostate cancer in young men: an important clinical entity. 
  • Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. 
  • Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. 
  • Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. 
  • Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. 
  • Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). 
  • Prostate cancer screening. 
  • Prostate cancer screening. Why the controversy? 
  • Prostate cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines. 
  • Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. 
  • Prostate cancer treatment unblinded. 
  • Prostate cancer with solitary parotid metastasis correctly diagnosed with immunohistochemical stains. 
  • Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. 
  • Prostate cancer, version 1.2014. 
  • Prostate cancer, version 2.2014. 
  • Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. 
  • Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. 
  • Prostate cancer. 
  • Prostate cancer: a significant risk factor for late-life suicide. 
  • Prostate cancer: active surveillance in African American men. 
  • Prostate cancer: an evolving paradigm. 
  • Prostate cancer: demographic and behavioral correlates of stage at diagnosis among blacks and whites in North Carolina. 
  • Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994. 
  • Prostate cancer: ideal candidates for focal therapy. 
  • Prostate cancer: making the switch from LHRH antagonist to LHRH agonist. 
  • Prostate cancer: status of current treatments and emerging antisense-based therapies. 
  • Prostate cancer: the new landscape. 
  • Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis. 
  • Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. 
  • Prostate intrafraction motion assessed by simultaneous kV fluoroscopy at MV delivery II: adaptive strategies. 
  • Prostate intrafraction motion assessed by simultaneous kilovoltage fluoroscopy at megavoltage delivery I: clinical observations and pattern analysis. 
  • Prostate intrafraction motion evaluation using kV fluoroscopy during treatment delivery: a feasibility and accuracy study. 
  • Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. 
  • Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men. 
  • Prostate specific antigen only progression of prostate cancer. 
  • Prostate specific antigen recurrence after definitive therapy. 
  • Prostate specific antigen: a decade of discovery--what we have learned and where we are going. 
  • Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. 
  • Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. 
  • Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. 
  • Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. 
  • Prostate-specific antigen as a marker of disease activity in prostate cancer. 
  • Prostate-specific antigen as a marker of disease activity in prostate cancer. 
  • Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. 
  • Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. 
  • Prostate-specific antigen screening among young men in the United States. 
  • Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995. 
  • Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. 
  • Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. 
  • Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility. 
  • Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. 
  • Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men. 
  • Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. 
  • Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens. 
  • Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials. 
  • Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. 
  • Prostatectomy vs brachytherapy for localized prostate cancer. 
  • Prostatic abscess as a delayed complication following cryosurgery for primary prostate cancer. 
  • Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: a relationship which may depend on genetic variation in ALA metabolism. 
  • Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. 
  • Prostatic disorders: MR imaging at 1.5 T. 
  • Prostatic malignancy. 
  • Prostatic mucinous adenocarcinoma. A Cowper gland carcinoma mimicker. 
  • Prostatic sarcoma with rapid tumor progression after nerve sparing radical cystoprostatectomy. 
  • Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. 
  • Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft. 
  • Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. 
  • Proteomics in prostate cancer. 
  • Psychological impact of diagnosis and risk reduction among cancer survivors. 
  • Psychosocial aspects of active surveillance. 
  • Psychosocial stress and prostate cancer: a theoretical model. 
  • Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer. 
  • Pubic Bone Osteomyelitis and Pubosymphyseal Urinary Fistula: A Poorly Recognized Complication in Prostate Cancer Survivors. 
  • Pubic Bone Resection Provides Objective Pain Control in the Prostate Cancer Survivor With Pubic Bone Osteomyelitis With an Associated Urinary Tract to Pubic Symphysis Fistula. 
  • Pubic symphysis osteomyelitis in the prostate cancer survivor: clinical presentation, evaluation, and management. 
  • Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. 
  • Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation: analysis of ten cases. 
  • Putting Provenge in perspective. 
  • QOL and outcomes research in prostate cancer patients with low socioeconomic status. 
  • Quality assurance for online adapted treatment plans: benchmarking and delivery monitoring simulation. 
  • Quality of life after prostate cancer treatment. 
  • Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. 
  • Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. 
  • Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. 
  • Quantification of prostate and seminal vesicle interfraction variation during IMRT. 
  • Quantifying the dosimetric trade-offs when using intensity-modulated radiotherapy to treat concave targets containing normal tissues. 
  • Quantitative comparison of automatic and manual IMRT optimization for prostate cancer: the benefits of DVH prediction. 
  • Quantitative evaluation of cone-beam computed tomography in target volume definition for offline image-guided radiation therapy of prostate cancer. 
  • Quantitative expression profile of PSGR in prostate cancer. 
  • Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. 
  • R726L androgen receptor mutation is uncommon in prostate cancer families in the united states. 
  • RNASEL mutations in hereditary prostate cancer. 
  • RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. 
  • Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. 
  • Race and the linkage between serum prostate-specific antigen and prostate cancer: a study of American veterans. 
  • Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center. 
  • Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. 
  • Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. 
  • Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy. 
  • Racial differences in prostate cancer risk remain among US servicemen with equal access to care. 
  • Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. 
  • Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. 
  • Radiation dose to the neurovascular bundles or penile bulb does not predict erectile dysfunction after prostate brachytherapy. 
  • Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort. 
  • Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate. 
  • Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients. 
  • Radical perineal prostatectomy. 
  • Radical perineal prostatectomy: a model for evaluating local response of prostate therapy. 
  • Radical perineal prostatectomy: oncological outcome during a 20-year period. 
  • Radical perineal vs. retropubic prostatectomy: a review of optimal application and technical considerations in the utilization of these exposures. 
  • Radical prostatectomy and cryotherapy--some answers, more questions. 
  • Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. 
  • Radical prostatectomy in stage A prostatic adenocarcinoma. 
  • Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma: the butcher and the baker selling their wares. 
  • Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment? 
  • Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. 
  • Radical prostatectomy. 
  • Radical prostatectomy: anatomical predictors of success or failure. 
  • Radical prostatectomy: the pros and cons of the perineal versus retropubic approach. 
  • Radical retropubic prostatectomy: the influence of accessory pudendal arteries on the recovery of sexual function. 
  • Radical surgery versus radiation therapy in early prostatic carcinoma. 
  • Radical surgery versus radiotherapy for adenocarcinoma of the prostate. 
  • Radioactive sources embedded in suture are associated with improved postimplant dosimetry in men treated with prostate brachytherapy. 
  • Radioimmunoassay of prostatic acid phosphatase in carcinoma of the prostate. 
  • Radioisotope bone scanning characteristics of metastatic skeletal deposits of prostatic adenocarcinoma. 
  • Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer. 
  • Radiotherapy following radical prostatectomy. 
  • Radiotherapy for locally recurrent prostate cancer. 
  • Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes. 
  • Radiotherapy versus surgery for localized prostatic cancer. 
  • Radiotherapy: Secondary malignancies after prostate cancer treatment. 
  • RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation. 
  • Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. 
  • Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). 
  • Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma. 
  • Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system. 
  • Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. 
  • Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. 
  • Re-purposing cryoablation: a combinatorial 'therapy' for the destruction of tissue. 
  • Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. 
  • Re: Dosimetric consequences of increased seed strength for I-125 prostate implants. Radiother Oncol. 2003 Sep;68(3):295-7. 
  • Re: Early detection of prostate cancer: AUA guideline: H. B. Carter, P. C. Albertsen, M. J. Barry, R. Etzioni, S. J. Freedland, K. L. Greene, L. Holmberg, P. Kantoff, B. R. Konety, M. H. Murad, D. F. Penson and A. L. Zietman J Urol 2013; 190: 419-426. 
  • Re: Guido Barbagli, Massimo Lazzeri. Clinical Experience with Urethral Reconstruction Using Tissue-engineered Oral Mucosa: A Quiet Revolution. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.043. 
  • Re: Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. 
  • Re: Osteoporosis after orchiectomy for prostate cancer. 
  • Re: Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J. S. Jones, A. Patel, L. Schoenfield, J. C. Rabets, C. D. Zippe and C. Magi-Galluzzi. J Urol, 175: 485-488, 2006. 
  • Re: p53 protein and gene alterations in pathological stage C prostate carcinoma. 
  • Reach out to ENhancE Wellness in Older Cancer Survivors (RENEW): design, methods and recruitment challenges of a home-based exercise and diet intervention to improve physical function among long-term survivors of breast, prostate, and colorectal cancer. 
  • Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. 
  • Reassessing the diagnostic yield of saturation biopsy of the prostate. 
  • Recent advances in the management of castration-resistant prostate cancer. 
  • Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells. 
  • Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. 
  • Recombinant human uteroglobin inhibits the in vitro invasiveness of human metastatic prostate tumor cells and the release of arachidonic acid stimulated by fibroblast-conditioned medium. 
  • Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. 
  • Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. 
  • Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. 
  • Rectal ejaculation and prostatic carcinoma. 
  • Rectourethral fistula after combination radiotherapy for prostate cancer. 
  • Rectourethral fistulas in the cancer survivor. 
  • Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. 
  • Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction. 
  • Relationship between body mass index and prostate cancer screening in the United States. 
  • Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. 
  • Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. 
  • Reliability and validity of PROMIS measures administered by telephone interview in a longitudinal localized prostate cancer study. 
  • Reply to Bora Lee and Jae Heon Kim's Letter to the Editor re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7. 
  • Reply to F. Valcamonico et al. 
  • Reply: To PMID 25432832. 
  • Report from Durham. 
  • Report from Durham. 
  • Report from Durham. 
  • Report from Durham. 
  • Resident involvement and experience do not affect perioperative complications following robotic prostatectomy. 
  • Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. 
  • Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer. 
  • Results from the Quality Research in Radiation Oncology (QRRO) survey: Evaluation of dosimetric outcomes for low-dose-rate prostate brachytherapy. 
  • Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). 
  • Results of radical prostatectomy in men with clinically localized prostate cancer. 
  • Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. 
  • Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. 
  • Review: alcohol and other factors related to late prostate radiation injury. 
  • Rhabdomyosarcoma in adult prostate. 
  • Rising PSA Level in an Anxious Postprostatectomy Patient. 
  • Rising PSA after local therapy failure: immediate vs deferred treatment. 
  • Rising PSA in nonmetastatic prostate cancer. 
  • Rising prostate-specific antigen after primary prostate cancer therapy. 
  • Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. 
  • Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary? 
  • Risk factors for perineal seeding of prostate cancer after needle biopsy. 
  • Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. 
  • Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study. 
  • Risk perception and concern among brothers of men with prostate carcinoma. 
  • Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy. 
  • Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. 
  • Role of oxidative stress in a rat model of radiation-induced erectile dysfunction. 
  • Role of salvage lymph node dissection in prostate cancer. 
  • Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer. 
  • Role of vitamin D(3) as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study. 
  • SV40-transformed hamster prostatic tissue: a model of human prostatic malignancy. 
  • Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. 
  • Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. 
  • Salvage radiation in men after prostate-specific antigen failure and the risk of death. 
  • Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. 
  • Sample size calculation for simulation-based multiple-testing procedures. 
  • Sample size calculations for evaluating a diagnostic test when the gold standard is missing at random. 
  • Sample size determination for comparing several survival curves with unequal allocations. 
  • Scanning and transmission electron microscopy of human prostatic acinar cells. 
  • Scanning electron microscopy of hyperplastic and neoplastic human prostate. 
  • Screening for familial and hereditary prostate cancer. 
  • Screening for prostate cancer in African Americans. 
  • Screening for prostate cancer in high risk populations. 
  • Screening for prostate cancer in military populations. 
  • Screening for prostate cancer utilizing the prostate-specific antigen (PSA). 
  • Second-line chemotherapy for advanced hormone-refractory prostate cancer. 
  • Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. 
  • Seduced by dose? 
  • Seduced by technology? 
  • Selective upregulated expression of the alpha2-macroglobulin signaling receptor in highly metastatic 1-LN prostate carcinoma cells. 
  • Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth. 
  • Semiparametric Bayesian modeling of random genetic effects in family-based association studies. 
  • Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer. 
  • Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men. 
  • Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy. 
  • Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. 
  • Serum androgens: associations with prostate cancer risk and hair patterning. 
  • Serum androgens: associations with prostate cancer risk and hair patterning. 
  • Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. 
  • Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. 
  • Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density. 
  • Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. 
  • Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. 
  • Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. 
  • Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction. 
  • Sexually transmitted infections and prostate cancer among men in the U.S. military. 
  • Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. 
  • Should function and bother be measured and reported separately for prostate cancer quality-of-life domains? 
  • Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. 
  • Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. 
  • Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. 
  • Similarities between static and rotational intensity-modulated plans. 
  • Simulation of electromagnetically induced hyperthermia: a finite element gridding method. 
  • Simulation optimization of PSA-threshold based prostate cancer screening policies. 
  • Single institution's dosimetry and IGRT analysis of prostate SBRT. 
  • Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. 
  • Slice-to-volume registration and its potential application to interventional MRI-guided radio-frequency thermal ablation of prostate cancer. 
  • Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. 
  • Smoking Is Associated with Acute and Chronic Prostatic Inflammation: Results from the REDUCE Study. 
  • Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study. 
  • Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. 
  • Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. 
  • Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. 
  • Special concerns for survivors of prostate cancer. 
  • Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. 
  • Spontaneously acquired anti-factor VIII antibodies: report of a patient with adenocarcinoma of the prostate. 
  • Squamous cell carcinoma of the prostate: 2 cases of a rare malignancy and review of the literature. 
  • Stability of self-reported family history of prostate cancer among African American men. 
  • Staging lymphadenectomy should not be an antecedent to treatment in localized prostatic carcinoma. 
  • Staging pelvic lymphadenectomy for carcinoma of the prostate risk versus benefit. 
  • Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. 
  • Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. 
  • Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer. 
  • Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. 
  • Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer. 
  • Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer. 
  • Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: The Hunt for the Silver Bullet. 
  • Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis. 
  • Strategies for automatic online treatment plan reoptimization using clinical treatment planning system: a planning parameters study. 
  • Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. 
  • Stress urinary incontinence in the prostate cancer survivor. 
  • Successful fertilization and pregnancy outcome in in-vitro fertilization using cryopreserved/thawed spermatozoa from patients with malignant diseases. 
  • Successful outcome of artificial urinary sphincters in men with post-prostatectomy urinary incontinence despite adverse implantation features. 
  • Supplement use among men with prostate cancer. 
  • Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. 
  • Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer. 
  • Surface-enhanced Raman scattering detection and tracking of nanoprobes: enhanced uptake and nuclear targeting in single cells. 
  • Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. 
  • Surgical management of complex rectourethral fistulas in irradiated and nonirradiated patients. 
  • Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. 
  • Symptoms, weight loss, and physical function in a lifestyle intervention study of older cancer survivors. 
  • Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression. 
  • Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. 
  • Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. 
  • Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone? 
  • Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. 
  • Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. 
  • Systemic strategies for prostate cancer. 
  • Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. 
  • TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. 
  • Targeted Anterior Gland Focal Therapy-a Novel Treatment Option for a Better Defined Disease. 
  • Targeted prostate biopsies: the complexity behind a simple concept. 
  • Targeting the androgen receptor--theory and practice. 
  • Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study. 
  • Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. 
  • Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. 
  • Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. 
  • Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy. 
  • The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. 
  • The CLN3 gene is a novel molecular target for cancer drug discovery. 
  • The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. 
  • The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer. 
  • The Diet Quality Index-Revised: a tool to promote and evaluate dietary change among older cancer survivors enrolled in a home-based intervention trial. 
  • The Escherichia coli subtilase cytotoxin A subunit specifically cleaves cell-surface GRP78 protein and abolishes COOH-terminal-dependent signaling. 
  • The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies. 
  • The Molecular Taxonomy of Primary Prostate Cancer. 
  • The National Cancer Data Base report on prostate cancer. 
  • The Physician Recommendation Coding System (PhyReCS): A Reliable and Valid Method to Quantify the Strength of Physician Recommendations During Clinical Encounters. 
  • The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. 
  • The Role of CD44 in Glucose Metabolism in Prostatic Small Cell Neuroendocrine Carcinoma. 
  • The STAMPEDE trial and celecoxib: how to adapt? 
  • The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke Prostate Center database. 
  • The UroLume stent revisited: the Duke experience. 
  • The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. 
  • The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. 
  • The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study. 
  • The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiation. 
  • The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort. 
  • The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. 
  • The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. 
  • The association of exercise with both erectile and sexual function in black and white men. 
  • The association of oncogenic human papillomaviruses with urologic malignancy. The controversies and clinical implications. 
  • The changing face of prostate cancer. 
  • The characteristics of bladder cancer after radiotherapy for prostate cancer. 
  • The clinical spectrum of prostate cancer. 
  • The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. 
  • The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. 
  • The critical use of population-based medical databases for prostate cancer research. 
  • The development of a web- and a print-based decision aid for prostate cancer screening. 
  • The development of erectile dysfunction in men treated for prostate cancer. 
  • The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. 
  • The dynamics of death in prostate cancer. 
  • The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. 
  • The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. 
  • The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer. 
  • The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. 
  • The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. 
  • The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy. 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. 
  • The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study. 
  • The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma. 
  • The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. 
  • The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. 
  • The ethics of hypofractionation for prostate cancer. 
  • The experiences of unpartnered men with prostate cancer: a qualitative analysis. 
  • The homeodomain protein HOXB13 regulates the cellular response to androgens. 
  • The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy? 
  • The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. 
  • The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. 
  • The interplay between obesity and the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer. 
  • The management of clinically localized prostate cancer. A summary of the Consensus Statement of the National Institutes of Health. 
  • The metabolic co-regulator PGC1α suppresses prostate cancer metastasis. 
  • The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study. 
  • The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. 
  • The optimisation of wedge filters in radiotherapy of the prostate. 
  • The optimization and inherent limitations of 3D conformal radiotherapy treatment plans of the prostate. 
  • The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. 
  • The posterior surgical approach to robot-assisted radical prostatectomy facilitates dissection of large glands. 
  • The prognostic role of lymphadenectomy in adenocarcinoma of the prostate. 
  • The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. 
  • The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism. 
  • The ratio of prostate chips with cancer: a new measure of tumor extent and its relationship to grade and prognosis. 
  • The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. 
  • The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer. 
  • The relevance of stage A malignancy in prostatic cancer. 
  • The role of androgen deprivation therapy combined with prostate brachytherapy. 
  • The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. 
  • The role of focal therapy in the management of localised prostate cancer: a systematic review. 
  • The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. 
  • The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. 
  • The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL. 
  • The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. 
  • The role of seminal vesicle motion in target margin assessment for online image-guided radiotherapy for prostate cancer. 
  • The role of surgery in stage B-2 malignancy. 
  • The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. 
  • The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? 
  • The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. 
  • The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. 
  • The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors. 
  • The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. 
  • The value of a baseline bone scan in patients with newly diagnosed prostate cancer. 
  • The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. 
  • The value of prostate specific antigen (PSA) density and free: total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation. 
  • The watchful waiting management option for older men with prostate cancer: state of the science. 
  • Therapeutic properties of aerobic training after a cancer diagnosis: more than a one-trick pony? 
  • Three-dimensional computer-simulated prostate models: lateral prostate biopsies increase the detection rate of prostate cancer. 
  • Time for a neoadjuvant chemotherapy strategy in prostate cancer? 
  • Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. 
  • Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. 
  • Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells. 
  • Tissue microarray assessment of prostate cancer tumor proliferation in African- American and white men. 
  • Tortuous and aberrant external iliac artery precluding radical retropubic prostatectomy for prostate cancer. 
  • Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer. 
  • Tradeoffs of integrating real-time tracking into IGRT for prostate cancer treatment. 
  • Traditional approaches to androgen deprivation therapy. 
  • Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate. 
  • Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. 
  • Transcription factor TFII-I causes transcriptional upregulation of GRP78 synthesis in prostate cancer cells. 
  • Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. 
  • Transrectal gene therapy of the prostate in the canine model. 
  • Treating the biochemical recurrence of prostate cancer after definitive primary therapy. 
  • Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs. 
  • Treatment of PSA only recurrence of prostate cancer after prior local therapy. 
  • Treatment of locally confined prostatic cancer. Radiotherapy versus surgery: limits of curability. 
  • Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy. 
  • Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. 
  • Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review. 
  • Treatment planning for prostate brachytherapy using region of interest adjoint functions and a greedy heuristic. 
  • Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome. 
  • Trefoil factor 1 acts to suppress senescence induced by oncogene activation during the cellular transformation process. 
  • TrueNTH sexual recovery study protocol: a multi-institutional collaborative approach to developing and testing a web-based intervention for couples coping with the side-effects of prostate cancer treatment in a randomized controlled trial. 
  • Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers. 
  • Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk. 
  • Tumor Repression of VCaP Xenografts by a Pyrrole-Imidazole Polyamide. 
  • Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. 
  • Tumor length in prostate cancer. 
  • Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. 
  • Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. 
  • Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint. 
  • Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? 
  • Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. 
  • Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. 
  • Twenty-five year evolution of medical hormonal therapy for prostate cancer. 
  • Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population. 
  • Two-locus genome-wide linkage scan for prostate cancer susceptibility genes with an interaction effect. 
  • U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia. 
  • UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression. 
  • Uncertainty intervention for watchful waiting in prostate cancer. 
  • Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. 
  • Update in the management of patients with hormone-refractory prostate cancer. 
  • Update on brachytherapy in localized prostate cancer: the importance of dosimetry. 
  • Update on cryotherapy for prostate cancer in 2006. 
  • Update on outcomes research databases in prostate cancer 2006. 
  • Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. 
  • Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. 
  • Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. 
  • Ureteral reimplantation for inadvertent ureteral injury during radical perineal prostatectomy. 
  • Urethroplasty for radiotherapy induced bulbomembranous strictures: a multi-institutional experience. 
  • Urinary continence and quality of life in the first year after radical perineal prostatectomy. 
  • Urinary tract metastasis from renal carcinoma. 
  • Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. 
  • Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. 
  • Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. 
  • Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. 
  • Use of prostate-specific antigen in black men: age-adjusted reference ranges for maximal cancer detection. 
  • Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. 
  • Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. 
  • Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. 
  • Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer. 
  • Utility of LHRH antagonists for advanced prostate cancer. 
  • Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. 
  • Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. 
  • Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. 
  • Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy. 
  • Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. 
  • Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. 
  • Utilization of surgical procedures and racial disparity in the treatment of urinary incontinence after prostatectomy. 
  • Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. 
  • Utilizing knowledge from prior plans in the evaluation of quality assurance. 
  • Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. 
  • Validation of genome-wide prostate cancer associations in men of African descent. 
  • Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). 
  • Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. 
  • Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. 
  • Variables in predicting survival based on treating "PSA-only" relapse. 
  • Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. 
  • Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. 
  • Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. 
  • Vincristine, bleomycin, methotrexate, 5-fluorouracil, and prednisone in metastatic, hormonally unresponsive prostatic adenocarcinoma. 
  • Viral neoplastic transformation of hamster prostate tissue in vitro. 
  • Virus-induced genitourinary malignancy. Macromolecular identity. 
  • Vitamin D and prostate cancer: a prediagnostic study with stored sera. 
  • Vitamin D receptor polymorphisms and prostate cancer. 
  • Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis. 
  • Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). 
  • Volumetric-modulated arc therapy: effective and efficient end-to-end patient-specific quality assurance. 
  • Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. 
  • Watching, waiting and uncertainty in prostate cancer. 
  • We need better randomized comparison trials of prostate cancer. 
  • What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis? 
  • What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. 
  • What to order from the prostate cancer treatment menu? 
  • When should we pull the trigger for post-radical prostatectomy radiotherapy? 
  • When to diagnose and how to treat prostate cancer in the "not too fit" elderly. 
  • Will the future of health care lead to the end of the robotic golden years? 
  • Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example. 
  • Words of wisdom. Re: Tracking the clonal origin of lethal prostate cancer. 
  • X-linked inhibitor of apoptosis deficiency in the TRAMP mouse prostate cancer model. 
  • X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. 
  • XIAP as target for therapeutic apoptosis in prostate cancer. 
  • Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. 
  • [European Association of Urology. Position statement on screening for prostate cancer] 
  • c-Jun Contributes to Transcriptional Control of GNA12 Expression in Prostate Cancer Cells. 
  • hZip2 and hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands. 
  • iDQC anisotropy map imaging for tumor tissue characterization in vivo. 
  • p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. 
  • p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. 
  • p53 gene alterations in human prostate carcinoma. 
  • p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. 
  • p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. 
  • p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). 
  • p53 regulates the expression of the tumor suppressor gene maspin. 
  • p53-dependent induction of heat shock protein 27 (HSP27) expression. 
  • p63 expression profile in normal and malignant prostate epithelial cells. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Chen, Nan-kuei, Adjunct Associate Professor in the Department of Radiology, Radiology
  • Chitneni, Satish K., Assistant Professor of Radiology, Radiology
  • Grambow, Steven C., Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Inman, Brant Allen, Cary N. Robertson, MD, Associate Professor, Surgery, Urology
  • Koontz, Bridget Fey, Associate Professor of Radiation Oncology, Radiation Oncology
  • McDonnell, Donald Patrick, Chair, Department of Pharmacology & Cancer Biology, Pharmacology & Cancer Biology
  • Moorman, Patricia Gripka, Professor in Community and Family Medicine, Duke Cancer Institute
  • O'Daniel, Jennifer Colleen, Assistant Professor of Radiation Oncology, Radiation Oncology
  • Preminger, Glenn Michael, James F. Glenn, M.D. Professor of Urology, Surgery
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Reiman Jr., Robert Ellis, Associate Professor of Radiology, Radiology
  • Routh, Jonathan Charles, Paul H. Sherman, M.D. Associate Professor of Surgery, Pediatrics
  • Shinohara, Mari L., Associate Professor of Immunology, Immunology
  • Yoo, Sua, Associate Professor of Radiation Oncology, Radiation Oncology